This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a novel treatment to improve arteriovenous fistula function for end-stage kidney disease patients requiring hemodialysis. The $499,890 award to Pavaj Vascular Corporation will be used to evaluate the stability and biocompatibility of a nanoparticle-based therapy composed of 1,25(OH)2D3 (active vitamin D3) and to determine its long-term efficacy in reducing venous stenosis and neointimal hyperplasia in a porcine chronic kidney disease model. Successful completion of this project will provide data needed to apply for FDA Investigational New Drug approval to conduct first-in-human studies for this promising therapeutic approach to improving arteriovenous fistula patency and reducing the significant healthcare costs associated with maintaining functional vascular access for hemodialysis patients.
Generated 3/4/25, 5:44 AM